169 related articles for article (PubMed ID: 1261153)
1. Spironolactone. I. Disposition and metabolism.
Karim A; Zagarella J; Hribar J; Dooley M
Clin Pharmacol Ther; 1976 Feb; 19(2):158-69. PubMed ID: 1261153
[TBL] [Abstract][Full Text] [Related]
2. Spironolactone metabolism in man studied by gas chromatography-mass spectrometry.
Karim A; Hribar J; Aksamit W; Doherty M; Chinn LJ
Drug Metab Dispos; 1975; 3(6):467-78. PubMed ID: 1221
[TBL] [Abstract][Full Text] [Related]
3. Spironolactone. II. Bioavailability.
Karim A; Zagarella J; Hutsell TC; Chao A; Baltes BJ
Clin Pharmacol Ther; 1976 Feb; 19(2):170-6. PubMed ID: 1261154
[TBL] [Abstract][Full Text] [Related]
4. Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites.
Gardiner P; Schrode K; Quinlan D; Martin BK; Boreham DR; Rogers MS; Stubbs K; Smith M; Karim A
J Clin Pharmacol; 1989 Apr; 29(4):342-7. PubMed ID: 2723123
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of spironolactone in man.
Abshagen U; Rennekamp H; Luszpinski G
Naunyn Schmiedebergs Arch Pharmacol; 1976 Dec; 296(1):37-45. PubMed ID: 1012347
[TBL] [Abstract][Full Text] [Related]
6. Species differences in the metabolism and disposition of spironolactone.
Karim A; Kook C; Zitzewitz DJ; Zagarella J; Doherty M; Campion J
Drug Metab Dispos; 1976; 4(6):547-55. PubMed ID: 11976
[TBL] [Abstract][Full Text] [Related]
7. New insights into the pharmacokinetics of spironolactone.
Overdiek HW; Hermens WA; Merkus FW
Clin Pharmacol Ther; 1985 Oct; 38(4):469-74. PubMed ID: 4042530
[TBL] [Abstract][Full Text] [Related]
8. Spironolactone. III. Canrenone--maximum and minimum steady-state plasma levels.
Karim A; Zagarella J; Hutsell TC; Dooley M
Clin Pharmacol Ther; 1976 Feb; 19(2):177-82. PubMed ID: 1261155
[TBL] [Abstract][Full Text] [Related]
9. Effect of neomycin on the bioavailability of spironolactone: a single-dose study.
Bartle WR; Coates PE; Fisher MM; Louman FJ
Am J Hosp Pharm; 1979 Dec; 36(12):1701-3. PubMed ID: 525647
[TBL] [Abstract][Full Text] [Related]
10. Determination of canrenone, the major metabolite of spironolactone, in plasma and urine by high-performance liquid chromatography.
Krause W; Karras J; Jakobs U
J Chromatogr; 1983 Oct; 277():191-9. PubMed ID: 6643605
[TBL] [Abstract][Full Text] [Related]
11. Effect of spironolactone, potassium canrenoate and their common metabolite canrenone on serum digoxin measurement by digoxin III, a new digoxin immunoassay.
Dasgupta A; Tso G; Wells A
Ther Drug Monit; 2008 Dec; 30(6):744-7. PubMed ID: 18824952
[TBL] [Abstract][Full Text] [Related]
12. Development and validation of an HPLC method for the determination of spironolactone and its metabolites in paediatric plasma samples.
Sandall JM; Millership JS; Collier PS; McElnay JC
J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Jul; 839(1-2):36-44. PubMed ID: 16510319
[TBL] [Abstract][Full Text] [Related]
13. Validation of plasma and urinary canrenone for determination of bioavailability of spironolactone--comparison of tablets with solution/suspension.
Tidd MJ; Ramsay LE; Shelton JR; Palmer RF
Int J Clin Pharmacol Biopharm; 1977 May; 15(5):205-10. PubMed ID: 873663
[TBL] [Abstract][Full Text] [Related]
14. Enhancement by food of canrenone bioavailability from spironolactone.
Melander A; Danielson K; Scherstén B; Thulin T; Wåhlin E
Clin Pharmacol Ther; 1977 Jul; 22(1):100-3. PubMed ID: 872489
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of canrenone after oral administration of spironolactone and intravenous injection of canrenoate-K in healthy man.
Krause W; Karras J; Seifert W
Eur J Clin Pharmacol; 1983; 25(4):449-53. PubMed ID: 6653638
[TBL] [Abstract][Full Text] [Related]
16. Canrenone--the principal active metabolite of spironolactone?
Ramsay LE; Shelton JR; Wilkinson D; Tidd MJ
Br J Clin Pharmacol; 1976 Aug; 3(4):607-12. PubMed ID: 22216502
[TBL] [Abstract][Full Text] [Related]
17. Spironolactone: relationship between concentrations of dethioacetylated metabolite in human serum and milk.
Phelps DL; Karim A
J Pharm Sci; 1977 Aug; 66(8):1203. PubMed ID: 894512
[TBL] [Abstract][Full Text] [Related]
18. Abbott ARCHITECT clinical chemistry and immunoassay systems: digoxin assays are free of interferences from spironolactone, potassium canrenoate, and their common metabolite canrenone.
DeFrance A; Armbruster D; Petty D; Cooper KC; Dasgupta A
Ther Drug Monit; 2011 Feb; 33(1):128-31. PubMed ID: 21079546
[TBL] [Abstract][Full Text] [Related]
19. Canrenone and androgen receptor-active materials in plasma of cirrhotic patients during long-term K-canrenoate or spironolactone therapy.
Andriulli A; Arrigoni A; Gindro T; Karbowiak I; Buzzetti G; Armanini D
Digestion; 1989; 44(3):155-62. PubMed ID: 2697627
[TBL] [Abstract][Full Text] [Related]
20. Effect of spironolactone, potassium canrenoate, and their common metabolite canrenone on Dimension Vista Digoxin Assay.
Dasgupta A; Johnson MJ
J Clin Lab Anal; 2010; 24(6):413-7. PubMed ID: 21089173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
